HAI-2 Double Nickase Plasmid (h): sc-407762-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- HAI-2 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- HAI-2 Double Nickase Plasmid (h) and HAI-2 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting SPINT2. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HAI-2 Double Nickase Plasmid (h) | sc-407762-NIC | 20 µg | $410.00 | |||
HAI-2 Double Nickase Plasmid (h2) | sc-407762-NIC-2 | 20 µg | $410.00 |
SPINT2 encodes hepatocyte growth factor activator inhibitor 2 (HAI-2), a Kunitz-type serine protease inhibitor that restrains pericellular proteolysis by regulating membrane-anchored proteases such as matriptase (ST14) and related activators. By limiting protease-dependent activation of substrates including pro-HGF and downstream MET signaling, HAI-2 helps maintain epithelial barrier integrity, cell polarity, and controlled extracellular matrix remodeling. SPINT2 function is closely linked to pathways governing epithelial homeostasis, protease-activated signaling, and inflammatory responses, and dysregulation has been associated with aberrant tissue remodeling and cancer-relevant invasion phenotypes. Altered SPINT2 expression or genetic disruption is also implicated in congenital epithelial disorders and contributes to mechanistic studies of protease–inhibitor balance in human cells.
HAI-2 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the SPINT2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within SPINT2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt SPINT2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of SPINT2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.